Randomized,Double-blind,Placebo-controlled,Multicenter Study to Compare the Efficacy and Safety of Anlotinib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies(ALTER0703)
Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 20 Dec 2016
At a glance
- Drugs Anlotinib (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms ALTER0703
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 14 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 14 Dec 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Jul 2017.
- 14 Dec 2016 Status changed from recruiting to active, no longer recruiting.